Core Viewpoint - Foryou Medical Technology (01696) reported strong growth in new orders for Q3 2025, driven by performance in China, South Korea, and Thailand markets [1] Group 1: Financial Performance - The company achieved a double-digit year-on-year growth in unaudited revenue for the quarter [1] Group 2: Product Development and Market Expansion - The flagship multi-functional device, Alma Harmony, experienced steady growth during the quarter [1] - The company plans to enhance the penetration of the Soprano series in the Asia-Pacific region within the year [1] - There is a commitment to advance the commercial deployment of Universkin by Alma in the U.S. market [1] - The company is on track to orderly progress the commercialization of Daxif in mainland China [1]

Core Viewpoint - Foryou Medical Technology (01696) reported strong growth in new orders for Q3 2025, driven by performance in China, South Korea, and Thailand markets [1] Group 1: Financial Performance - The company achieved double-digit year-on-year growth in unaudited revenue for the quarter [1] Group 2: Product Development and Market Expansion - The flagship multi-functional device, Alma Harmony, experienced steady growth during the quarter [1] - The company plans to enhance the penetration of the Soprano series in the Asia-Pacific region within the year [1] - There is a commitment to advance the commercial deployment of Universkin by Alma in the U.S. market [1] - The company is on track to orderly progress the commercialization of Daxif in mainland China [1]

Core Viewpoint - Furuya Medical Technology (01696.HK) reported strong growth in new orders for Q3 2025, driven by performance in China, South Korea, and Thailand markets [1] Group 1: Financial Performance - The company achieved a double-digit year-on-year growth in unaudited revenue for the quarter [1] Group 2: Product Development and Market Expansion - The flagship multi-functional device, Alma Harmony, experienced steady growth during the quarter [1] - The company plans to enhance the penetration of the Soprano series in the Asia-Pacific region within the year [1] - There is a commitment to advance the commercial deployment of Universkin by Alma in the U.S. market [1] - The company is on track to orderly progress the commercialization of Daxif in mainland China [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 自願公告 業務更新 本公告由復銳醫療科技有限公司（「本公司」，連同其附屬公司統稱「本集團」）自願 發佈，以通知本公司股東及潛在投資者有關本集團的最新業務狀況。 本公司欣然宣布，本集團於二零二五年第三季度的新訂單保持強勁增長勢頭，主 要得益於中國、韓國及泰國市場的表現。旗下多功能旗艦設備Alma Harmony於 本季度實現穩健增長。因此，本集團本季度未經審核收益實現同比雙位數增長。 憑藉持續的市場開拓和需求挖掘，本集團將於年內進一步推動Soprano系列在亞 太地區的滲透，全力推進Universkin by Alma在美國市場的商業部署。同時，按計 劃有序推進達希斐在中國大陸的商業化進程。 Sisram Medical Ltd 復䢇醫療科技有限公司* （ 於 以 色 列 註 冊 成 立 的 有 限 公 司 ） （股份代號：1696） 本公告乃根據本公司董事會初步審閱本集團的未經審核營運數據初稿及董事會現 ...

Core Viewpoint - The financial report of Alma Medical Technology revealed a surprising decline in both revenue and profit, leading to a significant drop in stock price, marking the third consecutive day of decline [1][4]. Financial Performance - Revenue for the first half of 2025 was $165.5 million, a slight decrease of 1.9% year-on-year, primarily due to high interest rates in North America affecting consumer spending and geopolitical issues causing shipment delays in June [4][6]. - Net profit was $8.99 million, a substantial decline of 31.9% year-on-year, with adjusted net profit down 28.1% to $11.97 million, resulting in a net profit margin of 7.2% [4][5]. - Gross margin decreased from 62.5% in the same period last year to 60%, a drop of 2.4 percentage points [5]. Cash Flow and Liquidity - Operating cash flow showed a net outflow of $489,000, compared to a net inflow of $396,000 in the previous year, mainly due to increased working capital requirements (accounts receivable and inventory increased by approximately $30 million) [5]. - As of the end of the reporting period, cash and cash equivalents stood at $60.1 million, sufficient to cover short-term debts of $50.7 million, although liquidity is becoming tighter [5]. Business Segment Performance - The injection filling segment was a highlight, with revenue surging 218% due to the successful launch of Profhilo in Thailand and Revanesse in direct sales markets in the UK, Germany, and Australia [4][6]. - Revenue from energy source devices declined, with flagship products Harmony and Soprano series experiencing weak demand in North America, although the Asia-Pacific market continued to grow, partially offsetting the decline in Europe and the US [7]. Outlook - Despite the poor performance in the first half, the company is optimistic about the second half of 2025, expecting stronger revenue and profit driven by new orders [10][11]. - The company plans to focus on consolidating its leadership position in strategic growth regions, particularly in Asia-Pacific and North America, through direct sales expansion and targeted product launches [11].